
AUTHOR INDEX

Volume 1 1994

- Austin, DJ, 131
- Band, H, 99
- Betts, WH, 153
- Bonjouklian, R, 113
- Borlinghaus, R, 153
- Breaker, RR, 223
- Chen, X, 31
- Clardy, J, 113
- Cohen FE, 31
- Crabtree, GR, 131, 163
- Cushing, TD, 91
- Davidson, E, 31
- Egli, M, 39
- Ellis Jr, WR, 173
- Erlanson, DA, 79
- Evan, G, 137
- Ezaz-Nikpay, K, 235
- Fan, QR, 47
- Fegley, G, 31
- Finney, NS, 85
- Forbes, IJ, 153
- Fu, H, 205
- Gantzel, P, 231
- Goodman, M, 231
- Greenlee, W, 211
- Guy, RK, 107
- Hall, J, 185
- Häner, R, 185
- Hilvert, D, 201
- Holderman, MT, 119
- Hopwood, DA, 205
- Hung, DT, 67
- Hüsken, D, 185
- Jacobsen, EN, 85
- Jiang, X, 231
- Joyce, GF, 223
- Kapoor, TM, 163
- Kenyon, GL, 31
- Khosla, C, 205
- Kuntz, ID, 31
- Lander, AD, 73
- Lane, W S, 47
- Lee, AY, 113
- Lee, GK, 31
- Li, R, 31
- Li, Z, 31
- Lincoln, SF, 153
- Liu, J, 47
- Lubini, P, 39
- Martins, LJ, 173
- Mason, GGF, 197
- Matthews, DJ, 25
- McCormick, F, 7
- Mendis, C, 31
- Metallo, SJ, 143
- Min, C, 119
- Mitchison, TJ, 3
- Miyake, H, 163
- Moser, HE, 185
- Murray, AW, 191
- Myers, LC, 91
- Myers, P, 7
- Nakatani, Y, 11, 631
- Nayar, GP, 119
- Nerenberg, JB, 67
- Nicolaou, KC, 1, 57, 107
- Ourisson, G, 11, 631
- Paloma, LG, 107
- Patchett, AA, 211
- Pavel, EG, 173
- Payne, G, 99
- Pei, D, 99
- Pichon, C, 119
- Pieles, U, 185
- Pitsinos, EN, 57
- Prendergast, K, 211
- Pruschy, MN, 163
- Ring, CS, 31
- Rivero, R, 211
- Rivett, AJ, 197
- Roessner, CA, 119
- Rosenthal, PJ, 31
- Roush, WR, 31
- Saimoto, H, 57
- Santander, PJ, 119
- Schepartz, A, 143
- Schreiber, SL, 1, 67, 131, 163
- Scott, AI, 119
- Seamark, RF, 153
- Seed, B, 125
- Shao, H, 231
- Shoelson, SE, 99
- Smitka, TA, 113
- Sodeoka, M, 47
- Solomon, EI, 173
- Spencer, DM, 163
- Spencer, JB, 119
- Stolowich, NJ, 119
- Stolz, LA, 99
- Strader, CD, 211
- Theodorakis, EA, 57
- Underwood, DJ, 211
- Verdine, GL, 47, 79, 91, 235
- Wagner, G, 91
- Walsh, CT, 99
- Wang, J, 119
- Ward, AD, 153
- Wells, JA, 25
- Wrasidlo, W, 57, 107
- Zalewski, PD, 153
- Zürcher, W, 39
- Zwang, O, 31

SUBJECT INDEX

Volume 1 1994

The letters in parentheses refer to the following: X=Crosstalk, M=Minireview,
R=Review and A=Research Article

- Ada methyltransferase, of *Escherichia coli*, 91 (A)
Affinity, of SH2 domains, 99 (A)
Agonist, dimerization of antagonist to make, 125 (X)
Allostery, 125 (X), 131 (X)
Angiotensin II, model of receptor for, 211 (A)
Angiotensin II receptor, 211 (A)
Antibiotics, calicheamicin, 57 (A)
Antisense
 oligonucleotide-europium cleavage, 185 (A)
 using methylated RNA, 39 (A)
Antithrombin II, 73 (X)
Apoptosis, 137 (M)
 in response to calicheamicin, 57 (A)
 zinc fluxes in, 153 (A)
Asymmetric epoxidation, 85 (R)
Aziridine, 231 (A)
- Bcl-2, role in apoptosis, 137 (M)
bZIP proteins, 143 (A)
- Cadmium, and Ada methyltransferase, 91 (A)
Calicheamicin, cleavage of DNA by, 57 (A)
Catalysis, comparison of different methods, 85 (R)
Catalytic antibodies, 85 (R)
Cell cycle
 arrest by discodermolide enantiomers, 67 (A)
 cyclin dependent kinases in, 191 (X)
 and tumor suppressor genes, 7 (M)
Cell death, apoptotic, 137 (M)
 zinc fluxes in, 153 (A)
Chemical protein synthesis, 201 (M)
Cholesterol, in membrane structure, 11 (R)
Cis-trans isomerization, of peptide bond, 231 (A)
c-Myc, role in apoptosis, 137 (M)
Combinatorial chemistry
 of polyketides, 205 (A)
 potential use in synthesis of glycosaminoglycan
 mimics, 73 (X)
 towards a pharmacological genetics, 3 (X)
CREB, DNA binding specificity of, 143 (A)
Cyclic peptide, 113 (A)
Cyclin, 191 (X)
Cyclin-dependent kinases, regulation of, 191 (X)
- Depsipeptide ring, 113 (A)
Dimerization
 by FK1012, 163 (A)
 in signaling, 125 (X), 131 (X), 163 (A)
 of receptors, 125 (X), 131 (X)
Discodermolide, properties of, 67 (A)
- DNA
 cleavage by calicheamicin, 57 (A)
 DNA-RNA chimeras, 39 (A)
 enzyme, RNA cleavage by, 223 (A)
 methylation, 235 (A)
 repair, 235 (A)
 synthesis, 235 (A)
DNA-protein interaction
 Ada methyltransferase, 91 (A)
 half-site spacing, 143 (A)
 leucine zipper-containing proteins, 143 (A)
 mapping by crosslinking, 47 (A)
 NF- κ B p50, 47 (A)
 p53, 79 (M)
 sequence specificity, 143 (A)
Docking
 of antagonist into model of angiotensin II
 receptor, 211 (A)
 of cysteine protease inhibitor, 31 (A)
Domain motion, in signal transduction, 211 (A)
- Enantioselective, properties of discodermolide, 67 (A)
Eneidyne antibiotics, cleavage of DNA by, 57 (A)
Enzymes, comparison with other catalysts, 85 (R)
Europium, RNA cleavage by, 185 (A)
- Fibroblast growth factor, 73 (X)
FKBP12, 163 (A)
FK1012, 163 (A)
FK506, synthetic dimer of, 163 (A)
Fluorescent probe, for zinc, 153 (A)
Folding, of p53, 79 (M)
Fossil record, of terpenes, 11 (R)
- GCN4, DNA binding specificity of, 143 (A)
Genetic engineering
 of hydrogenobyrinic acid synthesis *in vitro*, 119 (A)
 of interfacial zinc site in human growth hormone
 and its receptor, 25 (A)
Glycosaminoglycans, binding sites on proteins, 73 (X)
G-protein coupled receptor, model of, 211 (A)
Growth hormone, binding to receptor,
 25 (A), 125 (X), 131 (X)
- Heparan sulfate, 73 (X)
Homology models
 of cysteine protease from malaria parasite, 25 (A)
 of G-protein coupled receptor, 211 (A)
Hydration, of nucleic acid structures, 39 (A)

- Hydrogenobyric acid, synthesis of, 119 (A)
Hypertension, 211 (A)
- ICE protease, 137 (M)
Immunosuppression, and discodermolide, 67 (A)
In vitro selection, 223 (A)
Iron, coordination in phthalate dioxygenase, 173 (A)
- Lactoferrin, 73 (X)
Lck tyrosine kinase, 99 (A)
Ligand binding, 131 (X)
Lipid chemistry, of terpenoids, 11 (R)
Lipoprotein lipase, 73 (X)
- Magnetic circular dichroism, of phthalate dioxygenase, 173 (A)
Malaria, inhibitor of trophozoite protease, 31 (A)
Membranes, evolution and structure of, 11 (R)
Metal
 binding
 to Ada protein, 91 (A)
 to engineered human growth hormone, 25 (A)
 to p53, 79 (M)
 conjugation to oligonucleotide, 185 (A)
 coordination, probed by MCD, 173 (A)
Metallopeptide, dimerizer of protein domains, 143 (A)
Methylation, and RNA stability, 39 (A)
Microchaete lottakensis, protease inhibitor from, 113 (A)
Minor groove, hydrophobic effect, 39 (A)
Molecular design, of taxol derivatives, 99 (A)
Multi-enzyme synthesis, 119 (A)
Mutational analysis, of p53, 79 (M)
Myc-Max family of oncogenes, 137 (M)
- Natural products
 calicheamicin, mimics of, 57 (A)
 discodermolide, 67 (A)
 serine protease inhibitor A90720A, 113 (A)
 taxol, water-soluble derivative of, 107 (A)
NF- κ B, DNA binding by, 47 (A)
Non-heme ferrous center, 173 (A)
N7-methylguanine, structure in DNA, 231 (A)
Nuclear magnetic resonance (NMR) spectroscopy
 in solution, of taxol derivative, 107 (A)
 of Ada methyltransferase, 91 (A)
 of DNA, 235 (A)
 of hydrogenobyric acid, 119 (A)
- Oxygen, activation by phthalate dioxygenase, 173 (A)
- Peptide fragments, methods for ligation, 201 (M)
p53
 and antitumor agents, 7 (M)
 mutants and structure of, 79 (M)
- Pharmacology, expansion by combinatorial chemistry, 3 (X)
Phosphopeptide, binding to SH2, 99 (A)
Photocrosslinking, by azide-containing DNA, 47 (A)
Phthalate dioxygenase, 173 (A)
Platelet factor four, 73 (X)
Polyketides
 polyketide biosynthesis, 205 (A)
 polyketide synthase (PKS), 205 (A)
Precorrin-6X, synthesis of, 119 (A)
Programmed cell death, 137 (M), 153 (A)
Prolactin receptor, growth hormone binding to, 25 (A)
Proteasome, 197 (M)
Proteinase inhibitor
 of malarial cysteine protease, 31 (A)
 trypsin inhibitor A90720A, structure of, 113 (A)
Protein engineering, of growth hormone receptor, 25 (A)
Protein synthesis, chemical methods for, 201 (M)
Proteolysis, 197 (M)
Proximity, in control of biological processes, 131 (X)
- Rb, and antitumor agents, 7 (M)
Receptors
 aggregation, 125 (X)
 angiotensin II, 211 (A)
 dimerization, 125 (X), 131 (X)
 growth hormone, 25 (A)
Rel transcription factors, DNA binding, 47 (A)
Ribonuclease, artificial, 185 (A)
Rieske site, of phthalate dioxygenase, 173 (A)
RNA
 cleavage
 by DNA enzyme, 223 (A)
 by europium ions, 185 (A)
 stability of 2'-OMe modified, 39 (A)
 structural model of 2'-OMe modified, 39 (A)
- Serine proteinase, inhibitor of, 113 (A)
SH2 domain, binding to phosphopeptides, 99 (A)
Signal transduction
 dimerization in, 131 (X), 163 (A)
 discodermolide in, 67 (A)
 in T-cell receptor model, 163 (A)
 SH2 domains, 99 (A)
Stereochemistry, of natural discodermolide, 67 (A)
Structure-based drug design, 31 (A)
Surface plasmon resonance, 99 (A)
Synthetic catalysts, 85 (R)
- Taxol, solution structure of, 107 (A)
T-cell receptor signaling, 163 (A)
Terpenoids, and membrane evolution, 11 (R)
Tilted amide bond, 231 (A)
Total synthesis, of discodermolide, 67 (A)
Tumor suppressor genes, 7 (M), 79 (M)
Transcription
 control of, 131 (X)

- factors, 47 (A), 143 (A)
Transition-state structure, in peptide bond isomerization, 231 (A)
Twisted amide bond, 231 (A)
2'-O-methyl RNA, structure in duplex, 39 (A)
- Ubiquitin, 197 (M)
Unnatural amino acids, in synthetic protein synthesis, 201 (M)
- Vitamin B₁₂, synthesis of precursor, 119 (A)
X-ray crystal structure
- of DNA with 2'-O-methylated ribonucleotide, 39 (A)
of glycosaminoglycan-binding proteins, 73 (X)
of p53, 79 (M)
of trypsin-A90720A complex, 113 (A)
- Zinc
in Ada methyltransferase, 91 (A)
engineered site in growth hormone-receptor binding, 25 (A)
fluxes in apoptosis 153 (A)
Zinquin, fluorescent probe for zinc, 153 (A)

AUTHOR INDEX

Volume 2 1995

- Adams, DJ, 533
Adams, J, 503
Admiraal, SJ, 729
Albrizio, M, 677
Allerson, CR, 667
Alonso, DOV, 305
Ambe, F, 385
Amstad, P, 13
Arze, R, 591
- Baden, DG, 533
Badger, A, 471
Baeuerle, PA, 13
Baltimore, D, 805
Banci, L, 377
Battersby, AR, 527
Bauer, KE, 107
Bayley, H, 99, 391
Beck, AK, 471
Beebe, LA, 683
Beinert, H, 781
Bell, C, 683
Benz, CC, 45
Berg, JM, 83, 91
Bergman, J, 841
Bernatowicz, M, 451
Bertini, I, 377
Bertozzi, CR, 703
Bestor, TH, 119
Bevilacqua, VLH, 91
Beyrich-Graf, X, 367
Blackburn, BK, 223
Boles, AR, 291
Bolgar, M, 451
Bossard, MJ, 471
Braha, O, 99
Braissant O, 261
Breaker, RR, 655
Bren, KL, 377
Brisette-Storkus, CS, 429
Brown, MJB, 583
Brownstein, M, 483
Brunton, LL, 601
Bukar, R, 107
Bunnage, ME, 601
Burley, SK, 77
Buss, JE, 787
- Carell, T, 171
Carrasco, MR, 205
Carter, P, 223
Caughey, B, 1, 807
Cerutti, P, 13
- Chakraborty, TK, 157
Chambers, WH, 429
Chaney, M, 483
Chang, C-y, 391
Chapman, KB, 325
Charlton, J, 741
Chau, JH-L, 621
Cheley, S, 99
Chen, J, 621
Choi, J, 471
Choi, S-K, 23
Churchill, MEA, 213
Clardy, J, 195, 471, 721
Cohen, FE, 305
Cohen, SB, 33
Collins, EJ, 401
Collins, N, 591
Cortés, J, 583
Cox, JM, 819
Coxon, A, 119
Cutter, AL, 583
Czarnik, AW, 423, 631
- D'Alessio, K, 471
Daggett, V, 305
Dawson, JH, 137
de Fougerolles, A, 639
Desvergne B, 261
Di Bilio, AJ, 489
Diederich, F, 139
Dilley, H, 107
Dodds, C, 483
Dunayevskiy, YM, 171
Dunitz, JD, 709
Dunnington, D, 471
- Eaton, BE, 633
Eckstein, J, 609
Ellenberger, T, 351
Ellington, AD, 291
Engqvist-Goldstein, Å, 107
Enomoto, S, 385
Erdmann, P, 367
Ewing, DF, 553
- Famulok, M, 543
Faucette, L, 471
Feistner, BD, 683
Ferentz, AE, 213
Flanagan, ME, 147
Fogel, DB, 317
Fogel, LJ, 317
- Fraley, ME, 33
Fraser, SE, 615
Frederick, CA, 409, 632
Freer, ST, 317
- Ganem, B, 195
Garboczi, DN, 401
Gawley, RE, 533
Gehlhaar, DK, 317
Geiduschek, EP, 123
Giese, B, 367
Gill, SC, 683
Gold, L, 633
Goldberg, AL, 503
Golomb, BA, 651
Gómez-Puyou, A, 847
Grantcharova, V, 213
Gray, HB, 377, 489
Green, LS, 683
Griffin Jr, EA, 761
Griffin, JH, 501
Guidot, DM, 741
- Han, H, 163
Hand, A, 471
Hansen, M, 229
Hayes, JJ, 127
Herschbach, DR, 803
Herschlag, D, 729
Heys, R, 471
Higgins, DL, 107
Hoffman, B, 483
Holt, DA, 471
Houchins, B, 483
Hunden, D, 483
Hunt, CA, 45
Hurley, L, 229, 457
- Imperiali, B, 751
Ingeborg, B, 847
Iverson, BL, 67
- Jammalamadaka, V, 45
Janjić, N, 683
Janmey, PA, 61
Jeglitsch, G, 533
Jellinek, D, 683
Johnson, D, 483
Johnson, RK, 471
Johnston, SA, 187
Jordan, MA, 569
Joyce, GF, 655
Jucker, FM, 683

- Kahne, D, 7
Kalivretenos, AG, 23
Kananishi, S, 385
Kanter, JR, 601
Katz, BA, 591
Kauvar, LM, 107
Kayyem, JF, 615
Kazmirski, SL, 305
Kealey, JT, 609
Khan, AU, 437
Khosla, C, 355
Kikuchi, K, 385
Kirschenheuter, GP, 741
Kiuchi, F, 527
Kocisko, DA, 807
Kodadek, T, 187, 267
Koide, K, 601
Kongaere, P, 471
Koppel, G, 483
Kumar, RM, 615, 827
Kushner, PJ, 45
Kwon, HJ, 517
- Langen, R, 489
Lansbury Jr, PT, 1, 163, 807
Lato, SM, 291
Lau, CY, 343
Leadlay, PF, 583
Lee, A, 223
Lee, AY, 195
Lee, JC, 721
Leeper, FJ, 527
Levy, MA, 471
Li, H, 841
Liddington, R, 515
Lippard, SJ, 409, 632
Liu, B, 591
Luengo, JJ, 471
Luisi, PL, 677
- Madar, DJ, 33
Marsters, Jr, JC, 787
Meade, TJ, 615
Michels Jr, WJ, 761
Minshull, J, 775
- Moore, PB, 365
Mordasini-Denti, T, 139
Mullins, S, 223
Munroe, DG, 343
Musier-Forsyth, K, 661
Myers, AG, 33
- Nakahara, H, 385
Nakamura, E, 385
Nakanishi, K, 23
- Newman-Tarr, T, 471
Niblack, B, 391
Nicolaou, KC, 157, 533, 601
Nordlund, P, 409, 632
- Oberholzer, T, 677
Onuchic, JN, 489
Orgel, LE, 363
Owens, R, 483
- Paloma, LG, 601
Patel, DJ, 827
Pérez-Montfort, R, 847
- Peterson, BR, 139
Petretta, M, 367
Pirrung, MC, 621
Porter, T, 471
Prusiner, SB, 305
Puglisi, JD, 581
Purich, DL, 449
Pyle, AM, 761
- Qin, Z, 761
- Rando, RR, 281
Rannug, A, 841
Rannug, U, 841
Rapraeger, AC, 645
Ratledge, C, 553
Raymond, GJ, 807
Rebek Jr, J, 171
Regan, JJ, 489
Reid, RC, 71
Rein, KS, 533
Reiss, P, 451
Rejto, PA, 317
Repine, JE, 741
Rickert, KW, 751
Rocke, DM, 107
Rodrigues, ML, 223
Rojo-Domínguez, A, 847
Rollins, SB, 147
Rosenzweig, AC, 409, 632
Rozamus, LW, 471
- Saavedra-Lira, E, 847
Santi, DV, 609
Sawamura, M, 517
Scanlan, TS, 45, 71
Schepartz, A, 819
Schmidt, KN, 13
Schreiber, SL, 53, 401, 517
Schroeder, R, 543
- Schwartz, M, 721
Schwitter, U, 367
Sharman, GJ, 553
Sherman, CJ, 317
Shi, Y, 83
Shimada, J, 517
Shokat, KM, 509
Shu, AYL, 471
Sies, H, 653
Simon, JA, 53
Sjöberg, U, 841
Skov, LK, 489
Sloan, LS, 819
Smith, D, 741
Sportsman, JR, 107
Springer, TA, 639
Staunton, J, 583
Stehlin, C, 661
Stein, R, 503
Stewart, JD, 195
Still, WC, 205
Strobel, G, 721
Stroud, RM, 591
Stubbe, JA, 793
Sueki, K, 385
Sullenger, BA, 249
Sun, D, 457
Sutherland, AJ, 171
Szostak, JW, 325
- Takahara, PM, 409, 632
Taylor, SS, 601
Taylor, WP, 713
Theodorakis, EA, 533
Tiebes, J, 533
Tokuyama, H, 385
Tom, NJ, 33
Tomasz, M, 575
Tsoi, CJ, 355
Turano, P, 377
- Usdin, T, 483
Usherwood, PNR, 23
- van der Donk, WA, 793
Verdine, GL, 213, 667
Verkhivker, GM, 317
Verma, IM, 719
Villar, HO, 107
von Ahsen, U, 543
Vouros, P, 171
- Wahli, W, 261
Walker, B, 99, 391
Wallis, MC, 543
Wang, Y, 281

Weber, HP, 157
Weiner, AM, 447
Weinreb, PH, 163
Weiss, GA, 401
Weissman, JS, 255
Westerholm, R, 841
Widlanski, TS, 713
Wiesmann, KEH, 583
Wiley, DC, 401
Williams, DH, 553
Williams, RM, 147

Williard, R, 45
Wilson, L, 569
Wilson, T, 437
Winkler, JR, 489
Wintner, EA, 171
Wirth, C, 223
Wolfe, SA, 213
Wu, Y-S, 91

Yamago, S, 385
Yamashita, DS, 471

Yang, X, 721
Yap, L-P, 661
Ye, X, 827
Yen, H-K, 471
Yun, S, 229

Zava, D, 45
Zein, N, 451
Zichi, DA, 633
Zubillaga, RA, 847

SUBJECT INDEX

Volume 2 1995

The letters in parentheses refer to the following: X=Crosstalk, M=Minireview, R=Review
and A=Research Article

- Acetylcholinesterase, inhibitor, 621 (A)
Actin, effect of (-) depudecin on, 517 (A)
Activation cascade, of mitomycin C, 575 (M)
Activation domain, of transcription factor, 187 (X)
Acute respiratory disease syndrome (ARDS), 741 (A)
ADEPT, 223 (A)
Adipogenesis, transcriptional control of, 261 (M)
Aequorea victoria, production of GFP, 119 (X)
Affinity, relationship to specificity, 633 (X)
Affinity fingerprinting, 107 (A)
Aggregates, of prion protein in scrapie infection, 807 (A)
Ah receptor, 841 (A)
Alkaline transition, of cytochrome *c*, 377 (A)
Alzheimer's disease, 1 (X), 163 (A), 305 (A)
Amino-glycosylic bond cleavage, 351 (M)
Aminoacyl-tRNA synthetase, 661 (A)
 β -Amyloid, seeding of fibrils by NAC, 163 (A)
Analogous
 of balanol, 601 (A)
 of rapamycin, 471 (A)
Angiogenesis, and inhibition of VPF/VEGF, 683 (A)
Antibiotics
 aminoglycosides, 281 (A), 291 (A)
 erythromycin, synthesis of, 583 (A)
 mitomycin C, 575 (M)
 neomycin, 543 (A)
Antibody, catalytic, 195 (R)
Antigen presentation
 role of the proteasome, 503 (M)
Antitumor agents
 calicheamicin, 7 (M)
 colchicine, 569 (X)
 (-)-depudecin, 517 (A)
 (+)-dynemicin A, 33 (A)
 enediynes, 451 (A)
 hedamycin, 229 (A)
 kedarcidin, 451 (A)
 maduropeptin, 451 (A)
 mitomycin C, 575 (M)
 neocarzinostatin, 451 (A)
 pluramycins, 229 (A), 457 (A)
 quinocarcin, 147, (A)
 taxol, 223 (A), 569 (X), 721 (A)
 vinblastine, 569 (X)
Apoptosis
 role of reactive oxygen species, 437 (R)
Archeabacteria, proteasome structure, 503 (M)
Assembly, of subunits, 99 (A), 391 (A), 751 (A)
ATP, mechanism of hydrolysis, 729 (A)
Auto-redox disproportionation, in DNA cleavage by
 quinocarcin, 147 (A)
Azurin, electron flow in, 489 (A)
Balanol, SAR studies of, 601 (A)
Bioorganic chemistry, Gordon research conference,
 501 (X)
Bioremediation, 775 (X)
Bovine immunodeficiency virus, Tat protein, complex
 with TAR RNA, 827 (A)
Brevetoxin, SAR studies, 533 (A)
C-type lectin
 in NK cell receptors, 429 (R)
 selectin domain, 703 (X)
Caged proteins, 391 (A)
Calcium, binding by fibrillin domain, 91 (A)
Calicheamicin, 7 (M)
Carbohydrate
 binding, by FGFs and their receptors, 645 (M)
 effect on folding, 751 (A)
 recognition
 by selectins, 703 (X)
 of DNA minor groove, 7 (M)
 in NK cell activation, 429 (R)
Carboxylate shift, in methane monooxygenase,
 409 (A); reprinted in issue 2.9
Catalase
 overexpression of, and inhibition of NF- κ B
 activation, 13 (A)
 removal of reactive oxygen species, 437 (R)
Catalytic mechanism
 amide bond cleavage by ribozyme, 67 (M)
 ATP hydrolysis, 729 (A)
 chorismate mutase, 195 (R)
 group II intron ribozyme, 761 (A)
 phosphoprotein phosphatases, 713 (M)
 ribonucleotide reductase, 793 (R)
 uracil-DNA glycosylase, 351 (M)
Cell cycle, role of the proteasome in regulation of,
 503 (M)
Cell division
 inhibition by blocking microtubule dynamics,
 569 (X)
Cephalosporin, taxol prodrug complex, 223 (A)
Chaperones, in protein folding, 255 (R)
Cholesterol, synthetic receptor binding, 139 (A)
Chorismate mutase, catalytic mechanism, 195 (R)
Chromatin, DNA structure in, 127 (R)
Chromoproteins, 451 (A)
Cis-trans isomerization, of peptide bond
 effect of glycosylation, 751 (A)
Class I MHC
 recognition by NK cells, 429, (R)
Cobyrinic acid, in biosynthesis of coenzyme B₁₂,
 527 (A)

- Coenzyme B₁₂, biosynthesis, 527 (A)
 Colchicine, anti-mitotic agent, 569 (X)
 Combinatorial chemistry
 high affinity/high specificity ligands, 633 (X)
 selection procedure from library, 171 (A)
 used to synthesize
 acetylcholinesterase inhibitor, 621 (A)
 C₃ symmetric receptor peptide ligands, 205 (A)
 estrogen agonists, 45 (A)
 human neutrophil elastase inhibitors, 741 (A)
 polyketides, 355 (R)
 serotonin reuptake inhibitors, 483, (A)
 trypsin inhibitors, 17 (A)
 Compartmentalization, of biochemical reactions, 677 (A)
 Computational surrogate, 107 (A)
 CREB, recognition of HTLV-1 TRE, 819 (A)
 Cyclase, 583 (A)
 Cyclooxygenase activity, of prostaglandin H₂ synthase (PGHS), 343, (X)
 Cyclophanes, macrotricyclic, as synthetic steroid receptors, 139 (A)
 Cytochrome *c*, pH dependent equilibria, 377 (A)
 Cytochrome *c* oxidase, 781 (M)
 Cytoskeleton, regulation by phosphatidylinositol lipids, 61 (X)
- (-)-Depudecin, synthesis of, 517 (A)
 Detransformation, by (-)-depudecin, 517 (A)
 Diacylglycerol (DAG), 61 (X)
 Dimerization
 of peptides in a protein crystal lattice, 591 (A)
 as a strategy for increasing specificity of binding, 267 (R)
 Dinuclear center
 in cytochrome *c* oxidase, 781 (M)
 in methane monooxygenase, 409 (A); reprinted in issue 2.9
 in serine/threonine phosphatases, 713 (M)
 Dioxin, binding to Ah receptor, 841 (A)
 Disulfide crosslinking
 of DNA, 213 (A)
 effect on glycosylation, 751 (A)
 in fibrillin, EGF-like domain, 91 (A)
 of peptides in a protein crystal lattice, 591 (A)
 of RNA, 667 (A)
 DNA
 alkylation, 229 (A), 457 (A)
 bending, 213 (A), 819 (A)
 binding, by transcription factors, 187 (X), 267 (R)
 cleavage
 by chromoproteins, 451 (A)
 by group II intron ribozyme, 761 (A)
 by quinocarcin, 147 (A)
 as a probe of chromatin structure, 127 (R)
 by radicals, 367 (A)
 conformation, in HTLV-1 TRE, 819 (A)
 crosslinking
 by intercalators, 127 (R)
 by mitomycin C, 575 (M)
 4'-DNA radical, 367 (A)
 enzyme, Mg²⁺-dependent, 655 (A)
 glycosylase, uracil-specific, 351 (M)
 hydroperoxides, 367 (A)
 modification, as a probe of chromatin structure, 127 (R)
 polymerase, processivity of, 123 (M)
 recognition
 by carbohydrate minor groove binders, 7 (M)
 by group II intron ribozyme, 761 (A)
 by hedamycin, 229 (A)
 by HMG proteins 213 (A)
 by HTLV-1 Tax, 819 (A)
 by mitomycin C, 575 (M)
 by NF-κB homodimer, 77 (M)
 by quinocarcin and analogs, 147 (A)
 by zinc-finger proteins, 83 (A)
 repair, base excision, 351 (M)
 replication, in liposomes, 677 (A)
 shuffling, for mutagenesis, 775 (X)
 unwinding, on TBP binding to TATA box, 457 (A)
 Docking, flexible, 317 (A)
 Dopamine reuptake, inhibition of, 483 (A)
 Drug delivery, by fullerene, 385 (A)
 Dynamic instability, of microtubules, 569 (X)
 (+)-Dynemicin A, synthesis of, 33 (A)
- Electron transfer, 489 (A), 781 (M)
 Electron tunneling, bridge-assisted, 489, (A)
 Electrospray mass spectrometry, in combinatorial chemistry, 171 (A)
 Endophytic fungus, 721 (A)
 Enhancer, transcriptional, 187 (X)
 Enthalpy-entropy compensation, 709 (M)
 Enzymes
 chorismate mutase, 205 (R)
 HIV-1 protease, 317 (A)
 methane monooxygenase, 409 (A); reprinted in issue 2.9
 polyketide synthetases, 355 (R), 583 (A)
 ribozymes
 evolution of, 67 (M); 291 (A)
 group II intron, 761 (A)
 5'-5' ligase, 325(A)
 RNA-cleaving DNA enzyme, 655 (A)
 thymidylate synthase, 615 (A)
 Epidermal growth factor, module, 91 (A)
 Estrogen, synthesis of agonists, 45 (A)
 Evolution
 of phosphotriesterase, 71 (M)
 of ribozymes, 67 (M), 291 (A)
 Exochelin MN, structure of, 553 (A)
- Farnesyl transferase, inhibition of, 787 (M)
 Fibrillin, domain folding, 91 (A)
 Fibroblast growth factor, 645 (M)
 Fingerprinting, of ligands, 107 (A)

- FKBP12
 complex with FRAP and rapamycin, 471 (A)
 domain of rapamycin responsible for binding to, 157 (A)
- Fluorescent
 ligands, of MHC class I, 401 (A)
 proteins, GFP, 119 (X)
 resonance energy transfer, 119 (X)
 sensors, 423 (X)
- Fluoxetine, 483, (A)
- Folate, cofactor in thymidylate synthase, 609 (A)
- FRAP (TOR/RAFT1)
 complex with FKBP12 and rapamycin, 471 (A)
 rapamycin derivative without FRAP effector domain, 157 (A)
- Fullerene, biological behavior, 385 (A)
- Gene therapy,
 imaging agents for detecting gene delivery,
- Genetic engineering, of polyketide synthesis, 355 (R), 583 (A)
 615 (A)
 ribozymes in, 249 (X)
- Glycosaminoglycan, 645 (M)
- Glycosylation
 role in protein folding, 751 (A)
- Grb2, SH3 domain binding to Sos peptide, 53 (A)
- Green fluorescent protein (GFP), 119 (X)
- GTP
 hydrolysis, 729 (A)
- β -Hairpin, in BIV Tat peptide-TAR RNA complex, 827 (A)
- Heat stability, of liposomes undergoing PCR, 677 (A)
- Hedamycin, 229 (A)
- Heme, groups in cytochrome *c* oxidase, 781 (M)
- α -Hemolysin, 99 (A), 391 (A)
- Heparan sulfate, 645 (M)
- Histone H1, cleavage by chromoproteins, 451 (A)
- HIV-1 protease, inhibitor design, 317 (A)
- HMG proteins, 213 (A)
- HTLV-1, Tax protein, 819 (A)
- Human neutrophil elastase, 741 (A)
- Hydrogen bonding
 in enthalpy-entropy compensation, 709 (M)
- Hydrophobic cluster, in prion protein peptide, 305 (A)
- Hydroxystilbene, combinatorial library, 45 (A)
- I- κ B, mechanism of inhibition of NF- κ B, 77 (M)
- Immunodeficiency virus, bovine, 827 (A)
- Immunoglobulin superfamily
 interaction with integrins, 639 (M)
- Immunosuppressants
 rapamycin
 SAR of analogs, 471 (A)
 isolation of FKBP12-binding domain, 157 (A)
- Inflammation
 inhibiting prostaglandin's role in, 343, (X)
- role of integrins, 639 (M)
 role of leukocytes, 703 (X)
 role of the proteasome, 503 (M)
 role of selectins, 703 (X)
- Inositol trisphosphate (IP₃), protein regulation by, 61 (X)
- Integrin
 structure, 639 (M)
- In vitro* conversion, of PrP^C to PrP^{Sc}, 807 (A)
- In vitro* selection
 high affinity/high specificity ligands, 633 (X)
 kanamycin-binding RNAs, 291 (A)
 5'-5' ligase ribozyme, 325 (A)
 lividomycin-binding RNAs, 291 (A)
 Mg²⁺-dependent DNA enzyme, 655 (A)
 neomycin-binding RNAs, 543 (A)
 nuclease-resistant ligands to VPF/VEGF, 683 (A)
 ribozymes, 67 (M)
 tobramycin-binding RNAs, 281 (A)
- Iron, coordination, in methane monooxygenase, 409(A); reprinted in issue 2.9
- Kanamycin, RNA binding by, 291 (A)
- Kedarcidin, 451 (A)
- Kinetic traps and intermediates, in protein folding, 255 (R)
- Leprosy, and iron transport by exochelin MN, 553 (A)
- Ligase, 5'-5', 325 (A)
- Lipid metabolism, transcriptional regulation of, 261 (M)
- Lipids, polyphosphatidylinositol, 61 (X)
- Lipophilicity, of fullerene, 385 (A)
- Liposomes, PCR in, 677 (A)
- Lividomycin, RNA binding by, 291 (A)
- Maduropeptin, 451 (A)
- Magnetic resonance imaging (MRI), of DNA uptake 615 (A)
- Major histocompatibility complex (MHC),
 recognition by NK cells, 429 (R)
 synthesis of ligands, 401 (A)
- Marfan syndrome, 91 (A)
- Membrane permeabilization,
 with α -hemolysin, 99 (A), 391 (A)
 triggered by light, 391 (A)
 triggered by zinc ions, 99 (A)
- Methane monooxygenase, soluble (sMMO), 409 (A); reprinted in issue 2.9
- Methylmethane thiosulfonate (MMTS), 847 (A)
- Microtubule dynamics, 569 (X)
- Minor groove, carbohydrate-based binders, 7 (M)
- Mitomycin C, 575 (M)
- Molecular dynamics, simulations on
 peptide from prion protein, 305 (A)
- Molecular modeling
 of balanol, 601 (A)
 of HIV-1 protease inhibitor, AG-1343, 317 (A)

- of pluramycin–TBP–TATA-box complex, 457 (A)
- of serotonin reuptake inhibitory peptide, 483 (A)
- of synthetic steroid receptors, 139 (A)
- Molecular recognition
 - by architecture-specific DNA-binding protein, 213 (A)
 - in BIV Tat peptide–TAR RNA structure, 827 (A)
 - by C₃ symmetric, peptide-binding receptor, 205 (A)
 - by carbohydrate minor-groove binders, 7 (M)
 - by cyclophanes, 139 (A)
 - by group II intron ribozyme, 761 (A)
 - by HIV-1 protease, 317 (A)
 - of HTLV-1 TRE, 819 (A)
 - between immunoglobulin superfamily members and integrins, 639 (M)
 - by macrocyclic receptors, 205 (A)
 - prediction by affinity fingerprinting, 107 (A)
 - by prolyl-tRNA synthetase, 661 (A)
 - by synthetic peptide receptors, 205 (A)
 - by synthetic steroid receptors, 139 (A)
- Molecular switch, 99 (A), 391 (A)
- Mutagenesis, to generate new catabolic pathways, 775 (X)
- NAC, Alzheimer's peptide, role in seeding amyloid fibrils, 163 (A)
- Natural killer (NK) cells, 429 (R)
- Natural products
 - altromycin B, 229 (A)
 - angucyclines, 355 (R)
 - anthracyclines, 355 (R)
 - balanol, 601 (A)
 - benzoisochromanquinones, 355 (R)
 - brevetoxin, 533 (A)
 - calicheamicin, 7 (M)
 - chromomycin A₃, 7 (M)
 - (–)-depudecin, 517 (A)
 - (+)-dynemicin A, 33 (A)
 - erythromycin, 281 (A), 355 (R), 583 (A)
 - fluoxetine, 483 (A)
 - gentamycin, 281 (A)
 - hedamycin, 229 (A)
 - hydroxypestalopyrone, 721 (A)
 - kanamycin, 291 (A)
 - kedarcidin, 451 (A)
 - lividomycin, 291 (A)
 - macrolides, 355 (R)
 - maduropeptin, 451 (A)
 - neocarzinostatin, 451 (A)
 - pestalopyrone, 721 (A)
 - pestalosite, 721 (A)
 - philanthotoxin-433, 23 (A)
 - polyketides, 355 (R), 583 (A)
 - pluramycin, 229 (A), 457 (A)
 - quinocarcin, 147 (A)
 - rapamycin, 157 (A), 471 (A)
 - taxol, 569 (X), 721 (A)
 - prodrug, 223 (A)
 - tetracenomycins, 355 (R)
 - tetracyclines, 355 (R)
 - tetrazomine, 147 (A)
 - tobramycin, 281 (A)
 - Neocarzinostatin, 451 (A)
 - Neomycin, RNA binding by, 543 (A)
 - Netropsin, conjugated to quinocarcin, 147 (A)
 - NF-κB
 - activation by reactive oxygen species, 13 (A), 436 (R)
 - crystal structure in complex with DNA, 77 (M)
 - degradation by the proteasome, 503 (M)
 - PGHS1, role in activation, 343 (X)
 - structure of homodimer bound to DNA, 77 (M)
 - Nicotinic acetylcholine receptor
 - interaction with philanthotoxin, 23 (A)
 - role of glycosylation in folding and assembly, 751 (A)
 - Non-steroidal anti-inflammatory drugs (NSAIDs), 343 (X)
 - Nuclear hormone receptor, in adipogenesis, 261 (M)
 - Nuclear magnetic resonance (NMR) spectroscopy
 - of BIV Tat peptide–TAR RNA structure, 827 (A)
 - of C₃ symmetric, peptide-binding receptors, 205 (A)
 - of coenzyme B₁₂ biosynthesis intermediates, 527 (A)
 - of cyclophane, 139 (A)
 - of (–)-depudecin and analogs, 517 (A)
 - of disulfide cross-linked RNA, 667 (A)
 - of disulfide cross-linked DNA, 213 (A)
 - of (+)-dynemicin A and analogs, 33 (A)
 - of exochelin MN, 553 (A)
 - of fibrillin, EGF-like domain, 91 (A)
 - of hedamycin–DNA adduct, 229 (A)
 - of nAChR α-subunit peptide, 751 (A)
 - of quinocarcin analogs, 147 (A)
 - of rapamycin-based FKBP12 ligand, 157 (A)
 - of tryptophan-derived Ah receptor ligands, 841 (A)
 - of yeast Met80Ala-iso-1-cytochrome c, 377 (A)
 - Nuclease resistance, of RNA, 683 (A)
 - Nucleation, of amyloid fibril seed, 1 (X), 163 (A), 807 (A)
 - Nucleotide base triple, in BIV Tat peptide–TAR RNA complex, 827 (A)
 - Nucleotide inhibitors, of ribonucleotide reductase, 793 (R)
 - Okadaic acid, 13 (A)
 - Origin of living cells, 677 (A)
 - Oxygen
 - reactive species of,
 - activation of NF-κB by, 13 (A), 437 (R)
 - and induction of apoptosis, 437 (R)
 - and systemic acquired resistance, 437 (R)
 - singlet, as probe of DNA structure, 127 (R)
 - Paramagnetic NMR, 377 (A)
 - Paraoxon, degradation of, 71 (M)
 - Peroxidase activity, of prostaglandin synthase, 343 (X)
 - Peroxisome proliferator activated receptors, 261 (M)
 - Pestalotiopsis microspora*, 721 (A)

- Pharmacokinetics, of fullerene, 385 (A)
- pH-dependent equilibria, of cytochrome *c*, 377 (A)
- Phenanthridine, in MHC class I ligands, 401 (A)
- Philanthotoxin, interaction with nAChR, 23 (A)
- Phosphatases, phosphoprotein 713 (M)
- Phosphatidylinositol lipids, in protein regulation, 61 (X)
- Phosphotriesterase (PTE), evolution of, 71 (M)
- Photoactivation, of pore-forming protein, 391 (A)
- Photoaffinity labeling, of nAChR, 23 (A)
- Phytotoxins, 721 (A)
- Pluramycins, 229 (A), 457 (A)
- Pollutants, biodegradation of, 775 (X)
- Polychlorinated biphenyls (PCBs), 775 (X)
- Polycyclic aromatic hydrocarbons (PAHs), 775 (X)
- Polyketide
 - polyketide biosynthesis, 355 (R);583 (A)
 - polyketide synthase (PKS), 355 (R); 583 (A)
- Polylysine, 615 (A)
- Polymerase chain reaction
 - in liposomes, 677 (A)
- Polyphosphoinositides (PPIs), 61 (X)
- Pore formation, by α -hemolysin, 99 (A), 391 (A)
- Porphyrin, biosynthesis of, 527 (A)
- Prediction, of ligand binding by fingerprinting, 107 (A)
- Prenylation, inhibition of 787 (M)
- Prions
 - aggregates in prion protein conversion, 807 (A)
 - model of infectivity, 1 (X), 807 (A)
 - molecular dynamic simulations of prion protein peptide, 305 (A)
 - role of NAC in amyloid fibril formation, 163 (A)
- Processivity, of DNA polymerase, 123 (M)
- Prodrug, cephalosporin-taxol, 223 (A)
- Proliferating cell nuclear antigen (PCNA), 123 (M)
- Proline isomerization
 - effect of glycosylation, 751 (A)
- Proline-tRNA synthetase, 661 (A)
- Prostaglandin synthesis, 343 (X)
- Prostaglandin H₂ synthase (PGHS), 343, (X)
- Protease resistance, of PrP^{Sc}, 807 (A)
- Proteasome, structure, 503 (M)
- Protein folding
 - of fibrillin, EGF-like domain, 91 (A)
 - multiple pathways of, 255 (M)
 - role of glycosylation, 751 (A)
- Protein kinase A (PKA), inhibition by balanol, 601 (A)
- Protein kinase C (PKC), inhibition by balanol, 601 (A)
- Proteolysis
 - of histone H1 by chromoproteins, 451 (A)
 - by the proteasome, 503 (M)
- Proton pump, cytochrome *c* oxidase, 781 (M)
- Quinocarcin, DNA cleavage by, 147 (A)
- Radicals,
 - in DNA cleavage, 7 (M), 367 (A)
- as probes of DNA structure, 127 (R)
- in ribonucleotide reductase catalysis, 793 (R)
- Rapamycin
 - isolation of FKBP12-binding domain, 157 (A)
 - SAR of analogs, 471 (A)
- Ras
 - activation by tyrosine kinases, 509 (M)
 - adaptor protein, Grb2, 53 (A)
 - farnesylation of, 787 (M)
 - transformed cells, detransformation of, 517 (A)
- Reactive oxygen species
 - activation of NF- κ B by, 13 (A), 437 (R)
 - induction of apoptosis by, 437 (R)
 - production by quinocarcin, 147 (A)
 - and systemic acquired resistance (SAR), 437 (R)
- Receptor
 - NK-cell receptors, 429 (R)
 - receptor tyrosine kinase, 645 (M)
 - synthetic, for peptides, 205 (A)
- Receptor complex assembly
 - nAChR, 751 (A)
- Receptor-ligand complex
 - FGF/FGFR/heparan sulfate, 645 (M)
- Rel, transcription factor family, 77 (M)
- Ribonucleotide reductase, catalytic mechanism of, 793 (R)
- Ribonucleoprotein, in splicing, 249 (X)
- Ribozyme
 - DNA ribozyme, Mg²⁺-dependent, 655 (A)
 - evolution of, 67 (M); 291 (A)
 - in gene therapy, 249 (X)
 - group II intron, 761 (A)
 - with 5'-5' ligase activity, 325 (A)
- Ricin, ability to process crosslinked RNA, 667 (A)
- RNA
 - cleavage
 - group II intron ribozyme, 761 (A)
 - Mg²⁺-dependent DNA enzyme, 655 (A)
 - modification
 - disulfide crosslink, 667 (A)
 - nuclease resistant, 683 (A)
 - recognition
 - by group II intron ribozyme, 761 (A)
 - by kanamycin, 291 (A)
 - by lividomycin
 - by neomycin, 543 (A)
 - by BIV Tat protein, 827 (A)
 - by tobramycin, 281 (A)
 - splicing and editing, 249 (X)
 - world, 325 (A)
- RNA glycosylase, 667 (A)
- rRNA, binding by neomycin, 543 (A)
- Scrapie infection, 1 (X), 163 (A), 305 (A), 807 (A)
- Seeding, of amyloid fibril formation, 1 (X), 163 (A), 807 (A)
- Selectin, 703 (X)
- SELEX
 - human neutrophil elastase inhibitors, 741 (R)

- high affinity/high specificity ligands, 633 (X)
nuclease resistant ligands to VPF/VEGF, 683 (A)
Serine/threonine phosphatase, 713 (M)
Serotonin reuptake, inhibition of, 483 (A)
SH3, domain of Grb2, 53 (A)
Siderophore, exochelin MN, 533 (A)
Signal transduction
 activation of NF- κ B, 13 (A)
 in natural killer cells, 429 (M)
 role of farnesylation, 787 (M)
 role of peroxisome proliferator activated receptors, 261 (M)
 role of phosphatidylinositol lipids, 61 (M)
 role of reactive oxygen species, 437 (R)
 role of tyrosine kinases, 509 (M)
 SH3–ligand interactions, 53 (A)
Sliding clamp, of DNA polymerase processivity factors, 123 (M)
Sodium channel, effect of brevetoxin and analogs, 533 (A)
Son of sevenless, peptide of, binding to Grb2, 53 (A)
Sp1, 83 (A)
Species-specific inhibition, of TIM, 847 (A)
Specificity
 of carbohydrate minor groove binders, 7 (M)
 of DNA cleavage by quinocarcin, 147 (A)
 of mitomycin C, 575 (M)
 relationship to affinity, 633 (X)
 species-specificity of inhibition, 847 (A)
 in transcription factor binding, 267 (R)
 of tyrosine kinases, 509 (M)
Spermine, quinocarcin conjugate, 147 (A)
Splicing, of RNA, self- and *trans*-, 249 (X)
Src-homology (SH) domains, 509 (M)
Staphylococcal α -hemolysin, pore formation by, 99 (A) 391 (A)
Stem-loop, structure of neomycin-binding RNA, 543 (A)
Steroid recognition, by synthetic receptors, 139 (A)
Streptavidin, peptide crosslinking in crystals, 591 (A)
Structure-based design
 of C₃ symmetric, peptide-binding receptor, 205 (A)
 of HIV-1 protease inhibitor, 317 (A)
 of MHC class I ligands, 401 (A)
 of peptides for dimerization, 591 (A)
 of synthetic steroid receptor, 139 (A)
Subconductance state, of sodium channel, 533 (A)
Subunit, assembly, 99 (A), 391 (A), 751 (A)
Superoxide dismutase (SOD)
 overexpression of, and activation of NF- κ B, 13 (A)
 production of reactive oxygen species, 13 (A), 437 (R)
 α -Synuclein, role in amyloid formation, 163 (A)
- Tacrine, inhibition of acetylcholinesterase by, 621 (A)
Tat, protein from HIV, complex with TAR RNA, 827 (A)
TATA box
 regulation of transcription at, 267 (R)
 TBP binding to, 457 (A)
- Tax, protein from HTLV-1, 819 (A)
Taxol,
 cephalosporin–taxol prodrug, 223 (A)
 mechanism of action, 569 (X)
Tetrahydroacridine, inhibition of acetylcholinesterase by, 621 (A)
Thiyl radical, in ribonucleotide reductase, 793 (R)
Thymidylate synthase, mutagenesis, 609 (A)
Tobramycin, RNA binding by, 281 (A)
Topochemistry, in protein crystals, 591 (A)
Torreya taxifolia, 721 (A)
Toxicity
 of dioxin, 841 (A)
 of fullerene, 385 (A)
Transcription
 factors
 chimeric, 187 (X)
 NF- κ B, 77 (M)
 Peroxisome proliferator activated receptors, 261 (M)
 Rel, 77 (M)
 Sp1, 83 (A)
 strategies for specific binding, 267 (R)
 TATA-binding protein (TBP), 457 (A)
 modulation by chromatin structure, 127 (R)
Transferrin, for gene delivery, 615 (A)
Transition state, in ATP hydrolysis, 729 (A)
Transmissible spongiform encephalopathies, 1 (X), 163 (A), 305 (A), 807 (A)
TRE, HTLV-1 tat response element, 819 (A)
Triketide lactone, synthesis of, 583 (A)
Triosephosphate isomerase (TIM)
 barrel structure, 71 (M)
 species-specific inhibition of, 847 (A)
tRNA
 semi-synthetic, 661 (A)
 synthetase, molecular recognition by, 661 (A)
Trypanosoma Brucei, inhibition of TIM from, 847 (A)
Trypsin, inhibitor from combinatorial library, 171 (A)
Tryptophan
 conserved residue in thymidylate synthase, 609 (A)
 photoproducts as ligands for Ah receptor, 841 (A)
Tubulin, assembly in microtubules, 569 (X)
Tumor necrosis factor α , activation of NF- κ B, 13 (A)
Two-metal-ion center
 in serine/threonine phosphatases, 713 (M)
 in methane monooxygenase, 409 (A); reprinted in issue 2.9
Tyrosine kinase
 modular domain structure, 509 (M)
Tyrosine phosphatase, 713 (M)
Tyrosyl radical, in ribonucleotide reductase, 793 (R)
- Ubiquitin, and protein degradation, 503 (M)
Uracil-binding pocket, 351 (M)
Uracil-DNA glycosylase (UDGase), 351 (M)
- Vascular endothelial growth factor, ligands, 683 (A)

- Vascular permeability factor, ligands, 683 (A)
Vinblastine, anti-mitotic agent, 569 (X)
Vitamin B₁₂, biosynthesis, 527 (A)
- Water soluble
 combinatorial chemistry, 171 (A)
 fullerene, 385 (A)
 quinocarcin, 147 (A)
 synthetic steroid receptor, 139 (A)
Weak intermolecular interactions, 709 (M)
World Wide Web, Fluorescent Chemosensors and
 BioSensors Database, 423 (X)
- X-ray crystal structure
 archaeobacterial proteasome, 503 (M)
- cytochrome *c* oxidases, 781 (M)
FKBP12–rapamycin complexes, 471 (A)
integrin (Mac1), 639 (M)
methane monooxygenase, 409 (A); reprinted in
 issue 2.9
MHC class I, with bound ligand, 401 (A)
NF- κ B homodimer bound to DNA, 77 (M)
proliferating cell nuclear antigen, 123 (M)
streptavidin–peptide ligand complex, 591 (A)
VCAM-1, 639 (M)
Xenobiotics, evolution of catabolic pathways to
 degrade, 775 (X)
- Zinc-binding motif, in engineered α -hemolysin,
 99 (A)
Zinc-finger proteins, designed and natural, 83 (A)